Specific organ metastases and survival in small cell lung cancer

Abstract

Abstract. The aim of our retrospective study was to evaluate the clinicopathological features associated with distant metastasis from small cell lung cancer (SCLC). We reviewed patients diagnosed with SCLC metastasis at the time of presentation between 1999 and 2010. Among the consecutive 251 SCLC patients diagnosed, 152 (60.6%) patients had distant metastasis, of which 20.3, 18.3, 15.5, 10.0 and 6.0% of patients had liver, bone, brain, lung and adrenal gland metastasis, respectively. In a multivariate analysis using Cox's proportional hazards model, we identified that liver, bone and brain metastasis as well as the presence of pleural and/ or pericardial fluids were unfavorable prognostic factors. However, lung, adrenal gland and extrathoracic lymph node metastasis were not statistically significant prognostic factors. With regard to the treatment of SCLC patients, particularly those with liver, bone and brain metastasis or pleural and/or pericardial fluids, we should take the metastasizing organs into consideration.

Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis

“…In non-SCLC (NSCLC) as well as in SCLC, bone metastases indicated poor survival in population-based cohort studies [3,8]. In SCLC, patients with bone metastases also experienced poor survival in a study by Nakazawa et al [9] and in a population-based cohort study, which is consistent with our results. In our study, bone metastases were found in 26.2% of all patients with SCLC and 34.3% of the patients with SCLC-ED.…”

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

“…Postmortem analysis in both groups revealed that tumors had grown within the thoracic cavity or in the parathoracic region ( Figure 4, A and B). Some mice exhibited spontaneous metastases to the liver ( Figure 4A), which was not observed in the subcutaneous model; the liver is the most common site of distant metastases in SCLC patients (25). Monitoring tumor growth over time by bioluminescence imaging, we found that in this context, the CD47-blocking antibody also produced a significant inhibition of tumor growth ( Figure 4, C and D).…”

Lung cancer with spontaneous regression of primary and metastatic sites: A case report

“…Lung cancer metastasis to vascular-and lymphatic-associated organs is frequent and the most common metastatic sites are the lung, bone and brain (4)(5)(6). Lymph node involvement is primarily regional in cancers of the internal organs, including lung cancer (4,7).…”